Daily Archives: May 16, 2021

CAMBRIDGE, Mass. and FUCHU-SHI, Tokyo, May 12, 2021 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and TMS Co., Ltd. announced today that Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogens decision to acquire TMS-007 was based on positive data from a Phase 2a study. The study met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH) and demonstrated positive impacts on both blood vessel reopening in the brain as well as patient functional recovery. Patients were dosed up to 12 hours after the onset of stroke symptoms; average time to treatment was 9.5 hours for patients who received TMS-007 and 9.3 hours for those who received placebo. All patients who received TMS-007 were dosed beyond the time window of approved thrombolytic agents.

We are encouraged by these results and made the decision to acquire TMS-007 based on the totality of the safety, imaging and clinical outcome data from the Phase 2a study, said Alfred Sandrock, Jr., M.D., Ph.D., head of research and development at Biogen. It has been almost 25 years since the last thrombolytic agent was approved for acute ischemic stroke and we believe this novel investigational drug may expand the number of eligible patients who could potentially receive thrombolytic therapy and thus have a higher chance of functional independence after stroke.

Approved thrombolytic agents are limited in their use due to their benefit-risk profile in later time windows. According to the American Heart Association1, sICH is the most feared complication of the current thrombolytic therapy, tissue Plasminogen Activator (tPA), which works by dissolving blood clots that block blood flow to the brain. In time windows up to 9 hours after stroke onset, sICH has occurred in patients receiving tPA at rates as high as six percent in controlled studies.

The randomized, placebo-controlled, ascending dose Phase 2a study included 90 participants in Japan (n=52 TMS-007, n=38 placebo). The primary endpoint of the study evaluated safety as assessed by the incidence of sICH with worsening of National Institute of Health Stroke Scale of four points or more. There were no events reported in the patients who received TMS-007 compared to an incidence of three percent in the patients who received placebo.

In addition, TMS-007 demonstrated a significant improvement on the secondary endpoint of functional independence at 90 days, with 40 percent of patients who received TMS-007 achieving scores of 0 or 1 on the modified Rankin Scale, a measure of independence in daily living, indicating either no residual symptoms or no significant disability, compared to 18 percent of patients who received placebo (P=< 0.05). This was supported by objective angiographic evidence of recanalization in the subset of patients with a visible occlusion receiving TMS-007. The recanalization rate, as measured by magnetic resonance angiography, was 58.3 percent (14 out of 24) for patients who received TMS-007 compared to 26.7 percent (4 out of 15) for patients who received placebo (odds-ratio 4.23; 95 percent confidence interval (0.99, 18.07)).

Biogen will make a one-time $18 million payment as part of the acquisition of TMS-007. TMS is eligible to receive up to an additional $335 million in potential post-acquisition development and commercial payments should TMS-007 achieve certain developmental milestones and sales thresholds. TMS is also eligible to receive tiered royalties in the high single digits to sub-teen percentages on annual worldwide net sales. Biogen will be solely responsible for the costs and expenses related to the development, manufacturing and commercialization of TMS-007 following the acquisition.

Biogen is currently evaluating the next steps for the clinical development of TMS-007, including plans for global studies. Final data results from the Phase 2a study are expected to be communicated at a future scientific forum.

About Acute Ischemic StrokeStroke is a potentially debilitating or even deadly cerebrovascular event. It is the second leading cause of death worldwide, with about 13 million cases and 5.5 million deaths each year, and with lasting functional deficits in stroke survivors caused by irreversible damage to the brain. Caused by blockages of blood supply to the brain, acute ischemic stroke accounts for about 85 percent of all strokes, with no approved medical therapies for treatment beyond the 3 to 4.5-hour time window. There is a substantial unmet medical need for new therapies that can both improve clinical outcomes with improved efficacy and safety as well as extend the time after stroke onset that a patient can receive a thrombolytic treatment.

About TMS-007TMS-007 is a small molecule plasminogen activator with a proposed novel mechanism of action associated with breaking down blood clots and potentially inhibiting local inflammation at the site of thrombosis. This unique combination could position TMS-007 as a potential next generation thrombolytic for individuals with acute ischemic stroke with the aim to provide an extended treatment window as compared to currently approved thrombolytic agents.

About the Phase 2a StudyTMS-007 was evaluated in a multi-center, single-administration, double-blinded, randomized, placebo-controlled, ascending dose trial with three TMS-007 groups (1, 3 and 6 mg/kg) and a placebo group (52 patients who received TMS-007 and 38 patients who received placebo). The study run by TMS Co, Ltd., which took place in Japan, included patients with acute ischemic stroke within 12 hours after onset and ineligible for tissue Plasminogen Activator (tPA) or thrombectomy. The primary endpoint was evaluation of safety with secondary endpoints evaluating vessel recanalization as well as clinical outcomes at 90 days after stroke onset.

About BiogenAt Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the worlds first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimers disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

We routinely post information that may be important to investors on our website atwww.biogen.com. To learn more, please visitwww.biogen.comand follow us on social media Twitter, LinkedIn, Facebook, YouTube.

About TMS Co., Ltd.TMSCo., Ltd. is aprivatelyheld, clinical stage biotechnology company based in Fuchu-shi, Tokyo. The company was founded in 2005 to develop therapeutics based on novel discoveries to modulate the fibrinolytic system, identified by a team of scientists at TokyoUniversityof Agriculture and Technology (TUAT), led by Dr.KeijiHasumi, Professor of theUniversityand Chief Scientist of TMS.

Biogen Safe Harbor StatementThis news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about results from the Phase 2a study of TMS-007; the potential clinical effects of TMS-007; the potential benefits, safety and efficacy of TMS-007; clinical development programs, clinical trials, data readouts and presentations related to TMS-007; the potential of Biogens commercial business and pipeline programs, including TMS-007; Biogens strategy and plans; the identification and treatment of acute ischemic stroke; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as aim, anticipate, believe, could, estimate, expect, forecast, intend, may, plan, potential, possible, will, would and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, uncertainty of success in the development and potential commercialization of TMS-007; unexpected concerns may arise from additional data, analysis or results obtained during clinical studies; actual timing and enrollment of future studies of TMS-007; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogens drug candidates, including TMS-007; the occurrence of adverse safety events; the risks of other unexpected hurdles, costs or delays; failure to protect and enforce Biogens data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; third party collaboration risks; and the direct and indirect impacts of the ongoing COVID-19 pandemic on Biogens business, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogens expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogens most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogens current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Reference:

Read more:

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke - GlobeNewswire

InvestorPlace

On Wednesday, Ethereum (CCC:ETH-USD) co-founder Vitalik Buterin donated some $1 billion in Shiba Inu (CCC:SHIB-USD) crypto to help India fund its Covid-19 response. Source: shutterstock.com/JFunk The strange thing? Buterin never bought the Shiba coin himself. Instead, the Shiba community had gifted him the crypto as a joke. By sending him 50% of the outstanding coins, the gag went, the currency would become immune to a rug pull where controlling stakeholders hijack the coin for personal gain. Other joke cryptos from Akita Inu (CCC:AKITA-USD) to Dogelon Mars (CCC:ELON-USD) have since done the same.InvestorPlace - Stock Market News, Stock Advice & Trading Tips At the time, the 505 trillion Shiba coins were worth precisely $0, according to CoinMarketCap. Their first recorded price five months later a princely sum of $0.0000000013 would have valued Buterins coins at just $560,000. Fast forward to today and his SHIB coins alone are worth well over $9 billion. His other holdings add several billion more. 10 Dividend Aristocrat Stocks for Your Reliability Short List Already in 2021, cryptocurrencies have become one of the strangest financial manias in human history. Since January, digital currencies have added more than $1.3 trillion in market capitalization, growing far faster than the Nasdaq bubble of 1999. Traders have bought and sold trillions of dollars in cryptocurrency in the first five months of this year, even more than Americans spend on housing annually. As financial institutions start jumping into the fold, things will only get stranger. Much like the media giants of 1999, the U.S. banking sector of 2021 has begun rushing into an industry for fear of missing out. Whenever banks have run into an industry they dont quite understand, the results have always been the same: historians look back and ask, what on earth were those morons thinking? The 2021 Crypto Bubble: Echoes of 1999 So far, the rise of cryptocurrencies has followed the same pattern of most asset bubbles: A grain of truth emerges (the idea that cryptocurrencies can help grease the wheels of finance). As the dominant players win (i.e., Bitcoin (CCC:BTC-USD) and Ethereum rise), the initial grain of truth gets stretched to extremes (the idea that all cryptocurrencies must win). The bubble bursts, leaving speculators with severe losses. The 1999 tech bubble followed this arc to a tee. For example, in 1999, one University of Pennsylvania study counted no fewer than 1,500 online marketplaces, as companies scrambled to join the internet revolution. Legacy firms like Mattel (NASDAQ:MAT) and Time Warner (now owned by AT&T (NYSE:T)) went on to splash out billions in buying these unprofitable tech moonshots. But the bonanza didnt last. By 2004, only 31 had survived. Of those, only one public company 1-800Contacts ended with a price above its initial public offering. The remainder would spend years recouping lost share prices. (It would take Amazon (NASDAQ:AMZN) almost a decade to break out of its $90-range.) As for the legacy firms that bought in on fear? Time Warner would eventually write down 97% of AOLs value, while Mattel would sell The Learning Company for a catastrophic $27 million. Fools Rush In Legacy banks have already started feeling the echoes of 1999. Much like the rise of digital media companies, today digital currencies pose an existential threat to existing players. Every dollar of deposits lost to Bitcoin or central-bank digital currencies means less available for lending. Many point to Facebooks (NASDAQ:FB) Libra as the Sputnik Moment for banks. If a tech firm could issue a currency, why would customers need commercial banks? In response, bulge-bracket banks have rushed to develop in-house crypto platforms. Those without the means have started splashing out on acquisitions instead. According to PwC, a global consultancy, crypto deal-making already doubled in 2020 to $1.1 billion a minor but rapidly growing figure. Now, 2021 has turned out even stranger. This week, the Andreessen Horowitz-backed Internet Computer Price (CCC:ICP-USD) quickly hit a $45 billion valuation. Today, it is the ninth largest cryptocurrency in the world by market cap. Few developers back the new currency, but its star-studded team was enough for investors to buy in. This Time Its Worse: The Rise of ScamCoin Its no surprise that the 2021 crypto bubble has inflated far faster than the 1999 tech one. Unlike dot-com companies, a skilled programmer can create a new cryptocurrency within minutes. Many tokens on the Ethereum or Binance (CCC:BNB-USD) blockchain dont even bother with innovation coins like SafeMoon (CCC:SAFEMOON-USD) copy their code directly from existing tokens. CoinMarketCap now counts over 5,000 different digital currencies. Adding in Ethereum and Binances token contracts puts that figure well over 700,000. In April, one TikTok creator made a coin called SCAM to highlight the absurdities of these copycats. I just made the coin as a joke, said Andre Lewis. The internet had the last laugh, sending the coin to a $70 million valuation within an hour. Within four days, the token would reach a peak value of almost $12 billion before Lewis shut the entire project down. How did this happen? In their rush to adopt digital currencies, institutional investors have created an aura of legitimacy around cryptocurrencies. Today, firms from JPMorgan to Citibank publish glowing reports on six-digit price targets for Bitcoin. That means legitimate cryptocurrencies like Ethereum now trade alongside jokes like Shiba Inu. As more cryptocurrencies join the fold, it will become increasingly difficult to tell them apart. Will Any Crypto Win? To a certain extent, all cryptocurrencies essentially serve the same purpose to help investors record monetary and real-world transactions. Ethereum and its Ethereum killer competitors like Cardano (CCC:ADA-USD) and Polkadot (CCC:DOT-USD) track nonfungible items in the real world. Meanwhile, Bitcoin and competitors like Dogecoin (CCC:DOGE-USD) and Litecoin (CCC:LTC-USD) act as stores of digital value. That means the survival rate for cryptos will likely be lower than those seen by 1999 e-commerce companies. When coins like Litecoin and Dogecoin have practically zero technological differentiation, theres no practical reason for both to exist. Like past bubbles, retail investors will be the first ones to lose. Currencies like Dogecoin, SafeMoon and Shiba Inu have already lost traders billions from peak to trough. Copycats like Dogelon Mars, SafeMars (CCC:SAFEMARS-USD), and Akita Inu will likely keep these miniature boom-bust cycles going. But institutional investors will eventually inflate the broader bubble to a breaking point. From the Savings and Loan (S&L) Crisis of the 1980s to the mortgage-backed bonanza of the mid-2000s, financial institutions have a long history of taking good ideas to terrible extremes. Just like one Citigroup (NYSE:C) executive said in 2007, as long as the music is playing, youve got to get up and dance. In the near term, that means Bitcoin and its blue-chip altcoin counterparts will continue to see their values inflate. Financial institutions seem intent on keeping up with central banks and tech firms in adopting digital currencies. In the longer term, however, most cryptocurrencies will implode. Like Amazons competitors that went bankrupt, most of the 700,000 tokens today will disappear. Just like the 1999 bubble, well look back at 2021 a year where billions in Dogecoin rested on a single SNL performance and wonder what were those morons thinking? On the date of publication, Tom Yeung did not have (either directly or indirectly) any positions in the securities mentioned in this article. Tom Yeung, CFA, is a registered investment advisor on a mission to bring simplicity to the world of investing. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesnt matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2 Says Buy THIS Now The post SafeMoon, Shiba Inu, Dogecoin: The 2021 Crypto Bubble Is Unlike Anything Weve Seen appeared first on InvestorPlace.

Read more:

Results: EDAP TMS S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance

InvestorPlace

On Wednesday, Ethereum (CCC:ETH-USD) co-founder Vitalik Buterin donated some $1 billion in Shiba Inu (CCC:SHIB-USD) crypto to help India fund its Covid-19 response. Source: shutterstock.com/JFunk The strange thing? Buterin never bought the Shiba coin himself. Instead, the Shiba community had gifted him the crypto as a joke. By sending him 50% of the outstanding coins, the gag went, the currency would become immune to a rug pull where controlling stakeholders hijack the coin for personal gain. Other joke cryptos from Akita Inu (CCC:AKITA-USD) to Dogelon Mars (CCC:ELON-USD) have since done the same.InvestorPlace - Stock Market News, Stock Advice & Trading Tips At the time, the 505 trillion Shiba coins were worth precisely $0, according to CoinMarketCap. Their first recorded price five months later a princely sum of $0.0000000013 would have valued Buterins coins at just $560,000. Fast forward to today and his SHIB coins alone are worth well over $9 billion. His other holdings add several billion more. 10 Dividend Aristocrat Stocks for Your Reliability Short List Already in 2021, cryptocurrencies have become one of the strangest financial manias in human history. Since January, digital currencies have added more than $1.3 trillion in market capitalization, growing far faster than the Nasdaq bubble of 1999. Traders have bought and sold trillions of dollars in cryptocurrency in the first five months of this year, even more than Americans spend on housing annually. As financial institutions start jumping into the fold, things will only get stranger. Much like the media giants of 1999, the U.S. banking sector of 2021 has begun rushing into an industry for fear of missing out. Whenever banks have run into an industry they dont quite understand, the results have always been the same: historians look back and ask, what on earth were those morons thinking? The 2021 Crypto Bubble: Echoes of 1999 So far, the rise of cryptocurrencies has followed the same pattern of most asset bubbles: A grain of truth emerges (the idea that cryptocurrencies can help grease the wheels of finance). As the dominant players win (i.e., Bitcoin (CCC:BTC-USD) and Ethereum rise), the initial grain of truth gets stretched to extremes (the idea that all cryptocurrencies must win). The bubble bursts, leaving speculators with severe losses. The 1999 tech bubble followed this arc to a tee. For example, in 1999, one University of Pennsylvania study counted no fewer than 1,500 online marketplaces, as companies scrambled to join the internet revolution. Legacy firms like Mattel (NASDAQ:MAT) and Time Warner (now owned by AT&T (NYSE:T)) went on to splash out billions in buying these unprofitable tech moonshots. But the bonanza didnt last. By 2004, only 31 had survived. Of those, only one public company 1-800Contacts ended with a price above its initial public offering. The remainder would spend years recouping lost share prices. (It would take Amazon (NASDAQ:AMZN) almost a decade to break out of its $90-range.) As for the legacy firms that bought in on fear? Time Warner would eventually write down 97% of AOLs value, while Mattel would sell The Learning Company for a catastrophic $27 million. Fools Rush In Legacy banks have already started feeling the echoes of 1999. Much like the rise of digital media companies, today digital currencies pose an existential threat to existing players. Every dollar of deposits lost to Bitcoin or central-bank digital currencies means less available for lending. Many point to Facebooks (NASDAQ:FB) Libra as the Sputnik Moment for banks. If a tech firm could issue a currency, why would customers need commercial banks? In response, bulge-bracket banks have rushed to develop in-house crypto platforms. Those without the means have started splashing out on acquisitions instead. According to PwC, a global consultancy, crypto deal-making already doubled in 2020 to $1.1 billion a minor but rapidly growing figure. Now, 2021 has turned out even stranger. This week, the Andreessen Horowitz-backed Internet Computer Price (CCC:ICP-USD) quickly hit a $45 billion valuation. Today, it is the ninth largest cryptocurrency in the world by market cap. Few developers back the new currency, but its star-studded team was enough for investors to buy in. This Time Its Worse: The Rise of ScamCoin Its no surprise that the 2021 crypto bubble has inflated far faster than the 1999 tech one. Unlike dot-com companies, a skilled programmer can create a new cryptocurrency within minutes. Many tokens on the Ethereum or Binance (CCC:BNB-USD) blockchain dont even bother with innovation coins like SafeMoon (CCC:SAFEMOON-USD) copy their code directly from existing tokens. CoinMarketCap now counts over 5,000 different digital currencies. Adding in Ethereum and Binances token contracts puts that figure well over 700,000. In April, one TikTok creator made a coin called SCAM to highlight the absurdities of these copycats. I just made the coin as a joke, said Andre Lewis. The internet had the last laugh, sending the coin to a $70 million valuation within an hour. Within four days, the token would reach a peak value of almost $12 billion before Lewis shut the entire project down. How did this happen? In their rush to adopt digital currencies, institutional investors have created an aura of legitimacy around cryptocurrencies. Today, firms from JPMorgan to Citibank publish glowing reports on six-digit price targets for Bitcoin. That means legitimate cryptocurrencies like Ethereum now trade alongside jokes like Shiba Inu. As more cryptocurrencies join the fold, it will become increasingly difficult to tell them apart. Will Any Crypto Win? To a certain extent, all cryptocurrencies essentially serve the same purpose to help investors record monetary and real-world transactions. Ethereum and its Ethereum killer competitors like Cardano (CCC:ADA-USD) and Polkadot (CCC:DOT-USD) track nonfungible items in the real world. Meanwhile, Bitcoin and competitors like Dogecoin (CCC:DOGE-USD) and Litecoin (CCC:LTC-USD) act as stores of digital value. That means the survival rate for cryptos will likely be lower than those seen by 1999 e-commerce companies. When coins like Litecoin and Dogecoin have practically zero technological differentiation, theres no practical reason for both to exist. Like past bubbles, retail investors will be the first ones to lose. Currencies like Dogecoin, SafeMoon and Shiba Inu have already lost traders billions from peak to trough. Copycats like Dogelon Mars, SafeMars (CCC:SAFEMARS-USD), and Akita Inu will likely keep these miniature boom-bust cycles going. But institutional investors will eventually inflate the broader bubble to a breaking point. From the Savings and Loan (S&L) Crisis of the 1980s to the mortgage-backed bonanza of the mid-2000s, financial institutions have a long history of taking good ideas to terrible extremes. Just like one Citigroup (NYSE:C) executive said in 2007, as long as the music is playing, youve got to get up and dance. In the near term, that means Bitcoin and its blue-chip altcoin counterparts will continue to see their values inflate. Financial institutions seem intent on keeping up with central banks and tech firms in adopting digital currencies. In the longer term, however, most cryptocurrencies will implode. Like Amazons competitors that went bankrupt, most of the 700,000 tokens today will disappear. Just like the 1999 bubble, well look back at 2021 a year where billions in Dogecoin rested on a single SNL performance and wonder what were those morons thinking? On the date of publication, Tom Yeung did not have (either directly or indirectly) any positions in the securities mentioned in this article. Tom Yeung, CFA, is a registered investment advisor on a mission to bring simplicity to the world of investing. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesnt matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2 Says Buy THIS Now The post SafeMoon, Shiba Inu, Dogecoin: The 2021 Crypto Bubble Is Unlike Anything Weve Seen appeared first on InvestorPlace.

Read more here:

South Jersey MS Center Now Offering TMS Therapy For Those With Chronic Treatment-Resistant Illnesses - Yahoo Finance

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) with bullish sentiments.

EDAP TMS (EDAP)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on EDAP TMS today and set a price target of $12.00. The companys shares closed last Wednesday at $6.26.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 28.8% and a 47.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.

EDAP TMS has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, implying a 92.3% upside from current levels. In a report issued on April 28, Piper Sandler also initiated coverage with a Buy rating on the stock with a $13.00 price target.

See todays analyst top recommended stocks >>

Veru (VERU)

Oppenheimer analyst Leland Gershell maintained a Buy rating on Veru today and set a price target of $24.00. The companys shares closed last Wednesday at $7.24.

According to TipRanks.com, Gershell is a 3-star analyst with an average return of 2.1% and a 36.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $23.50 average price target.

Kamada (KMDA)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kamada, with a price target of $11.00. The companys shares closed last Wednesday at $5.86, close to its 52-week low of $5.78.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.7% and a 47.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA American, Constellation Pharmaceuticals, and Global Blood Therapeutics.

Currently, the analyst consensus on Kamada is a Moderate Buy with an average price target of $11.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Visit link:

Analysts Offer Insights on Healthcare Companies: EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) - Smarter Analyst

Whether youre at the end of your coffee, your day, your week or even your rope, welcome to Whitts End 5.14.21

*Not sure how the Dallas Cowboys are going to end, but Im dang skippy sure how theyre going to begin.

Oh-and-1.

The Sept. 9 opener against Tom Brady in the same stadium in which the Tampa Bay Buccaneers won Super Bowl LV seven months earlier is the ultimate setup. The Cowboys are merely attractive, ratings-grabbing fodder for the defending champs.

READ MORE: Dak: Dallas Cowboys NFL Opener Bigger Than Bucs

Itll be Dak Prescotts first game in almost a year since the devastating ankle injury. The Bucs could very well return all 22 starters. That includes, of course, Brady, whom the Cowboys have never beaten (0-5). And these much-ballyhooed games are almost always a layup for the champs. In the last 16 Thursday-night season openers, the hosts are 13-3.

Take Tampa Bay, lay the 6.5 points, cash in, and then chill.

READ MORE: WATCH: Cowboys NFL Schedule HYPE Video Feat Jerry Jones and Post Malone

Dont judge a season by the opponents cover. With Prescott improving and Dan Quinns new defense taking shape, the Cowboys at Thanksgiving will be a much better team than the Cowboys just after Labor Day.

*For my money, the best GM in DFW is calling it quits. Eddie Gossage took control of Texas Motor Speedway in 1995, two years before it hosted its first race. During his 25-year run he transformed TMS from a desolate pasture north of Fort Worth into one of the jewels of auto racing. A creative genius and tireless promoter, the 62-year-old Gossage will retire as the face of the track after TMS hosts NASCARs All-Star Race on June 13. Hed be good at anything, but for my money Gossage should step into NASCARs booth as an expert/insider analyst.

*Its preposterous to make a season prediction before any rookie takes a minicamp rep or the first training camp injury. So give me 10-7 for the Cowboys.

IF Tyron Smith, Zack Martin and Lael Collins hold up, the offense will be good enough to carry this team to the playoffs. If not, duck-Dak goose-goose eggs. Again.

*Were better than this. At least we should be. Just when you thought the bar was raised on this Dallas Mavericks season, everyone fans, announcers, even players is clamoring to merely get into the postseason by avoiding the dreaded Play-In Tournament.

Kristaps Porzingis is actually talking about the playoffs as "dessert.''

No, Mavs. This is the main course. This is the meal.

I get it. Sidestepping those one-and-done games is crucial to long-term playoff success. But shouldnt the Mavs have their sights set higher than just making the playoffs?

Yes, yes they should.

They havent won a playoff series, remember, in 10 years. Dallas caught a huge break late Thursday night when the Blazers blew a late lead in a loss at Phoenix. All they have to do to earn the Wests fifth seed is beat crappy Toronto and equally crappy Minnesota this weekend. Do that and theyll earn a favorable first-round matchup against a Nuggets team it has already beaten twice on the road and who will be without injured star Jamal Murray.

READ MORE: WATCH: Luka's Week - From Body Slam To Doncic's Dallas Playoff Pledge

We saw in the 2020 bubble what happens when the Mavs play the bigger, better Clippers and it isnt pretty. Sorry, but avoiding the Play-In only to lose another first-round series to the Clippers would be a major step back for the Mavs.

Raise the bar. Were better than this.

*Regardless of what the Blazers do, zero excuse for the Mavs not to win their final two games and finish 43-29. The Raptors come to American Airlines Center Friday night at 27-43, playing the second of a back-to-back and with a starting lineup of Jalen Harris, Malachi Flynn, Khem Birch, Stanley Johnson and Yuta Watanabe. Sundays finale is against the lottery-bound Timberwolves and their 22 wins.

*As has been the case since, oh, about March 11, 2020, Im confused about COVID. The CDC announces Thursday that all fully vaccinated Americans no longer have to wear a mask. Indoors. Outdoors. Anywheres. The Texas Rangers are among those "going for it.''

READ MORE: Face Coverings, Masks No Longer Required to Slow COVID At Rangers Games

Cool cool.

But two questions:

1. Wont vaccinated peeps now look identical to science-denying anti-vaxxers? I mean, this is the end of masks as we know them, right? You either dont believe in them or you dont need them. Either way, youre not wearing them.;

2. Mavs owner Mark Cuban says home playoff games at AAC can ramp up to 9,000 fans. But why not a sellout? Max capacity? Lets be serious, the only fans who shouldnt be allowed into stadiums maskless (see question No. 1) are those who havent been vaccinated and no one is motivated to admit that.

*Tim Tebow back in the NFL? Why not Tony Romo? That was a sarcastic bit of satire, people. But seriously, folks ... Why Tebow and not Kaepernick?

This is essentially the point Dez Bryant is making about a mid-30's Tebow getting yet another chance. I've called it "white privilege,'' but however you assess it, try it this way: Who is more likely, given the chance, to get open and catch a football: Dez or Tebow?

Now do we see how "political'' this all might really be?

*Using the same, perverted philosophy He and Urban Meyer were soooo chummy in college that it prompted the Jaguars to sign 34-year-old Tim Tebow and have him switch positions, Cowboys head coach Mike McCarthy should bring in 51-year-old Alex Van Pelt and have him back up Blake Jarwin at tight end. After all, the two were at Pitt together in 1992. Sound strategy, right?

*To say the least, a disappointing season for the Dallas Stars ended this week. Coming off a plucky run to the Stanley Cup Finals last summer and off to a 4-0 start by a combined score of 19-6 in late January, missing the playoffs seemed implausible. Until it wasnt. Easiest explanation: The Stars lost a league-high 14 games in overtime or shootout. Sports.

*Micah Parsons, middle linebacker. Book it.

*Just when I think Ive got my life under control, in the past week Ive run through an entire washer/dryer cycle: Sunglasses, Chapstick and an iPod. Checking pockets is just too difficult for me, apparently. None of the items, of course, survived the turbulent journey.

*Byron Nelson at TPC Craig Ranch > Byron Nelson at Trinity Forest. And its not even close. At the tournaments new home in McKinney are things we longed for during the failed two-year run in south Dallas. Amenities like trees, shade, concessions and, yes, a party pavilion for when the golf is over, or simply gets boring.

*Two cheating, lying, disgusting teams Im urging you to never ever let off the hook: the Houston Astros and Wells Fargo.

The Rangers are in Houston this weekend, as fine a reason as any to remember that they stole signs, wore buzzers and absurdly, blatantly stole the 2017 World Series via an elaborate scheme.

READ MORE: Full Rangers-Astros Coverage Here

In the wake of being exposed, the Astros fired their manager and general manager, but players such as Carlos Correa and Jose Altuve were never punished.

And before this weeks stop in McKinney, the PGA last week was at the Wells Fargo tournament. Over the weekend, Wells Fargo ran these cutesy TV commercials where actors comically second-guessed bank customers decisions. Vomit. Need I remind you that Wells Fargo is the same sleezy financial institution that agreed to a $3 billion settlement after admitting that over 14 years its employees opened millions of accounts in customers names without their knowledge, signed unwitting account holders up for credit cards and bill payment programs, created fake personal identification numbers, forged signatures and even secretly transferred customers money.

Neither of these businesses should be allowed to still be in operation. Boo them. Boycott them. Do anything but trust them.

*Hot.

*Not.

*I tend to use the word inexplicable too much. Guilty. I guess we all have our pet words. Our verbal and/or written crutches we lean on. With Fox NFL analyst Troy Aikman its the word football, as if we need constant reminding that the Cowboys are making mistakes that are going to cost them this footballgame. With Mavericks analyst Derek Harper its as a player, as if we need constant reminding that Luka is really putting his stamp on this game, as a player.

Both announcers go-tos are, dare I say, inexplicable.

*Dude was robbing banks around DFW and getting away with it until he left a deposit slip on a counter with a fingerprint on it. The Devil permanently resides in the details.

*Everyone has their nemesis. Superman has kryptonite. Lance Armstrong has lying. The Mavs cant beat the Sacramento Friggin Kings. And the Rangers cant solve the riddle that is the San Francisco Giants. Theyre 6-21 all-time, including 0-2 in the 2010 World Series.

*If it ever stops raining in DFW, summer will arrive. The hot gates of Hades will swing open and belch fireballs upon us and before you know it, youll be complaining about 100-degree temperatures and pouring sweat just walking outside. You can hide indoors and whine like you do every year or you can acclimate. Simple: Find a steam room. Sit in it. For three minutes. The next day for four. Then five. Eventually 15. Trust me, your mind and body will get comfortable with being uncomfortable and your Texas summer wont be such a bummer.

*Dak made more money in 2020 than Brady, LeBron James and Mookie Betts. He started two wins.

READ MORE: Dallas Cowboys QB Dak Prescott Named on Forbes' 'Highest-Paid'

Those three stars, meanwhile, combined for 139 victories and three championships. Hopefully the poor Dak sentiments have been eternally muted.

*To distinguish between the inmates (non-vaxxed) and the guards (vaxxed), can we at least issue those plastic, yellow VIP bracelets or something?

*Speaking of low Mavericks bars, they will win their fourth division championship this season. Unlike the NFL where division rivalries last and champions matter, I doubt if most Mavs fans can even name the other members of the Southwest. For what its worth, they would win maybe only one other division (Southeast) in the NBA with their record.

*Ill take Charlie Culberson on my team, any day.Not flashy, but the Rangers third baseman is wholly functional.

*I still have no clue about NFTs, but they seem cooler when adorned by art. Or are they the actual art? I give up.

*Considering his constant complaining, bevy of technical fouls and ugly low blow to an opposing player last week, is it fair to ask if Luka has an anger management problem?

*Lest this be of any surprise, the Kentucky Derby winner being stripped of its win because of a failed drug test is a reminder that at the top of the worlds dirtiest sports are boxing, horse racing and track & field.

*Lost in all the salivating over Seahawks receiver D.K. Metcalf running a 10.37 100-meter dash in a sanctioned event last week was this memory: Former Cowboy Bob Hayes ran a 10.10 100 to win the gold medal at the 1964 Olympics, then put on a helmet and caught 71 touchdowns over 10 seasons.

*Hard to believe we launched the satellite Voyager 1 in 1977 and its still though now flying beyond our solar system sending back data. Talk about exceeding expectations, the things predicted shelf life was five years.

*As a tennis geek this is totally depressing: There are no American men ranked in the worlds Top 30 for the first time since August 1973. And, honestly, no hotshot 17-year-olds on the rise to even give us hope.Where have you gone Connors, McEnroe, Sampras, Agassi and Courier?

*RANGERS RISK: We all think the Texas Rangers are going to be putrid this season. Our lil roundtable revealed predicted win totals of anywhere between 61 and 78, but no one thinks .500 is plausible. Lets put our money where our mouth is. Im going to bet a virtual $100 against the Rangers every game this season and, after six months and 162 games, see where I wind up. Ill keep a running tab right there each Friday and come September Ill (wink) disperse my profits to my most loyal readers. RECORD: 18-21. TOTAL: -$568.

*This Weekend? Friday is for playing golf with Dad in JoCo MoFo. Saturday morning is for playing tennis. Saturday afternoon is for watching golf at the Byron Nelson with family and friends. Welcome back, Spring in north Texas! As always, dont be a stranger.

Link:

The Dallas Cowboys Will Start 0-1 - And Win The NFC East - Sports Illustrated

DataIntelo has Published a brand-new market research study on the international Toll Management System(TMS) Market. This industry report incorporates comprehensive market analysis about the chances that has emerged as a result of this COVID-19 pandemic. Whats more, it gives key insights about the creative approaches which are used by leading business players amidst the pandemic.

Major Players Covered in the Report:

TollPlusTelegraConduent TransportationDonlenMike Albert Fleet SolutionsAitek-Aitek SpAKENT ITSRaytheonGreen Tech ITS

Get Free Sample Report: https://dataintelo.com/request-sample/?reportId=184814

The report covers the market drivers, restraints, threats, opportunities, and challenges which are anticipated to modify the dynamics of this market throughout the forecast period, 2021-2028. These afore-mentioned important parameters are expected to assist the reader make critical business decisions readily. The Toll Management System(TMS) market research report offers information regarding the drivers, restraints, chances, pricing variables & tendencies, gains, revenue generation, and emerging trends of this market.

5 Crucial Insights That Are Covered in the Toll Management System(TMS) Market Report

The global Toll Management System(TMS) market is segmented on the basis of:

Products

On-premiseCloud Based

Application

HighwayUrbanOthers

Regions

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Buy the complete report https://dataintelo.com/checkout/?reportId=184814

The Market Research report comprises revenue share, potential growth opportunities, and theorized growth rate of this market in above areas. DataIntelo has contemplated social-economic variables of the nations in the area to examine the regional market. Whats more, it has included the effect of the COVID-19 outbreak on the area and commerce regulations and government policies & policies which shapes the rise of the market in these areas.

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Toll Management System(TMS) Market Overview

Global Toll Management System(TMS) Market Analysis and Forecast by Type

Global Toll Management System(TMS) Market Analysis and Forecast by Application

Global Toll Management System(TMS) Market Analysis and Forecast by Sales Channel

Global Toll Management System(TMS) Market Analysis and Forecast by Region

North America Toll Management System(TMS) Market Analysis and Forecast

Latin America Toll Management System(TMS) Market Analysis and Forecast

Europe Toll Management System(TMS) Market Analysis and Forecast

Asia Pacific Toll Management System(TMS) Market Analysis and Forecast

Asia Pacific Toll Management System(TMS) Market Size and Volume Forecast by Application

Middle East & Africa Toll Management System(TMS) Market Analysis and Forecast

Competition Landscape

Why to Choose DataIntelo?

The companys research team has been constantly monitoring the Toll Management System(TMS) market since few years, which has helped them to include actionable insights that can confer the esteemed reader with the leverage to grow their enterprise with a high CAGR and gain stellar ROI in the market.

Many regions are observing the second wave of the COVID-19 pandemic that has persuaded industry players to reanalyse their decisions and deploy strategies for the new normal. The research team has conducted interviews with the industry experts and top-executives amidst the pandemic to get in-depth insights of the market in a detailed manner. They have used Porters Five Analysis and implemented robust methodology to understand the complex nature of the global Toll Management System(TMS) market.

The team provides quarterly updates of the market, that includes products latest developments, strategies implemented by top players, and latest trends of the market. Additionally, the research team can customize the report in accordance to the requirements.

Request for Exclusive Discount: https://dataintelo.com/ask-for-discount/?reportId=184814

DataIntelo Has extensive knowledge in the development of tailored market research reports in many industry verticals. We ensure in-depth market evaluation including producing creative business plans for the new entrants and also the emerging players of this marketplace. Our firm offers market hazard evaluation, market opportunity analysis, and profound insights into the present and market situation.

To supply the utmost quality of the research report, we spend in analysts which hold stellar Expertise in the company domain and also have excellent analytical and Communication abilities. Our committed staff undergo quarterly training that Helps them to admit the most recent industry practices and also to serve the Customers together with the foremost customer experience.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 414 1393

Email:[emailprotected]

Website:https://dataintelo.com

Read the rest here:

2021 Latest Insights On Toll Management System(TMS) Industry. Understand Market Future And Impact Of Covid-19 On The Industry Clark County Blog -...

The global Adjuvant Breast Cancer Therapy Market study estimates revenue and volume growth at the global, regional, and country levels, as well as an overview of the most recent industry developments in each sub-segment from to 2027.

Infinity Business Insights has segmented the global Adjuvant Breast Cancer Therapy Market report for the purposes of this study based on product, use, end-use, type, and area. The Adjuvant Breast Cancer Therapy Market research report offers not only projections and predictions, but also a straightforward assessment of these figures in terms of market dynamics. These Adjuvant Breast Cancer Therapy market insights combine a data-driven analysis framework with qualitative workshops for business managers, CXOs, politicians, and investors.

Major industry Players: Celgene, Bedford Laboratories, Kyowa Kirin, Genetech, R-Pharm US, AbbVie Inc, Mylan N.V, Eli Lily, Novartis, Merck & Co, Bayer, Johnson & Johnson,,AstraZenca

GET PDF version of the sample report @ https://www.infinitybusinessinsights.com/request_sample.php?id=382945

Adjuvant Breast Cancer Therapy industry -By Application:

Adjuvant Breast Cancer Therapy industry By Product:

Ask for Exclusive Discount @ https://www.infinitybusinessinsights.com/ask_for_discount.php?id=382945

Adjuvant Breast Cancer Therapy Market Forecast Years:

Inquiry Before Buying @ https://www.infinitybusinessinsights.com/enquiry_before_buying.php?id=382945

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

Continue reading here:

Global High-intensity Focused Ultrasound (HIFU) therapy Market 2021 Top 10 Key players |EDAP TMS, THERACLION, CARDIAWAVE, BrainSonix Corporation, FUS...